The Radoff-JEC Group, which owns approximately 7.7% of Seer Inc. (NASDAQ: SEER) shares, announced plans to nominate three directors for the company's board at the July 28, 2026 annual stockholder meeting.

The group, led by Bradley L. Radoff and Michael Torok, cited Seer's 97% share price decline since its December 2020 initial public offering as justification for leadership changes. According to the group's statement, Seer's stock fell from its IPO price through April 10, 2026.

The Radoff-JEC Group nominated Howard H. Berman, Ph.D., Joshua S. Horowitz, and Luis E. Rinaldini as independent director candidates. The group opposes the re-election of current Chairman and CEO Omid Farokhzad, M.D., along with directors Terrance McGuire and Dipchand Nishar.

The group's statement included performance data for other companies where Farokhzad held leadership roles. According to the filing, BIND Therapeutics filed for Chapter 11 bankruptcy protection, Selecta Biosciences' share price declined 93.7% between its IPO and merger with Cartesian Therapeutics, Tarveda Therapeutics was liquidated under court supervision, and Senti Biosciences Holdings' share price dropped 98.5% since its 2022 public listing.

Seer develops proteomics technology platforms for biological research and clinical applications. The company went public in December 2020 at $16 per share.

The proxy contest information was provided in a statement from the Radoff-JEC Group through Business Wire.